In 2003, Monnier et al.6 first proposed that FPG and PPG contribute to HbA1c in patients with type 2 diabetes mellitus (T2DM) being administered antidiabetic treatment except for insulin and acarbose. This evidence concerns the gene INS and type 2 diabetes mellitus.